Vibha Paul Rishi appointed as non-executive director to Piramal Pharma Board of Directors

Published On 2022-09-30 08:45 GMT   |   Update On 2022-09-30 08:45 GMT

Mumbai: Piramal Pharma Limited has announced the appointment of Ms. Vibha Paul Rishi as a non-executive director to its Board of Directors. Ms. Rishi is a marketing professional and has held global leadership positions across branding, strategy, innovation, and human capital. In the domains of marketing and innovation, she has been associated with PepsiCo, Max India Ltd., and the Future...

Login or Register to read the full article

Mumbai: Piramal Pharma Limited has announced the appointment of Ms. Vibha Paul Rishi as a non-executive director to its Board of Directors. 

Ms. Rishi is a marketing professional and has held global leadership positions across branding, strategy, innovation, and human capital. In the domains of marketing and innovation, she has been associated with PepsiCo, Max India Ltd., and the Future Group. Ms. Rishi currently serves on the Boards of several reputed companies, including Tata Chemicals Limited, ICICI Bank Limited, ICICI Prudential Life Insurance Company Limited, Asian Paints Limited, and others.

She is also on the Board of Pratham Education Foundation, an NGO that provides education to underprivileged children in India. She has joined the PPL Board, which consists of senior professionals with significant industry experience across multiple sectors.

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC's complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News